(Q50477490)

14 March 2018

title

Circulating tumor cells (CTCs) from metastatic breast cancer patients linked to decreased immune function and response to treatment. (English)

1 reference

14 March 2018

main subject

metastatic breast cancer

1 reference

1 reference

Taryn L Green

1

1 reference

14 March 2018

Julius M Cruse

series ordinal

2

1 reference

14 March 2018

Robert E Lewis

series ordinal

3

1 reference

14 March 2018

Barbara S Craft

series ordinal

4

1 reference

14 March 2018

publication date

4 July 2013

1 reference

14 March 2018

Experimental and Molecular Pathology

published in

1 reference

14 March 2018

volume

95

1 reference

14 March 2018

issue

2

1 reference

14 March 2018

page(s)

174-179

1 reference

14 March 2018

Progress in using circulating tumor cell information to improve metastatic breast cancer therapy

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2013.06.013

Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2013.06.013

Roles of toll-like receptors in cancer: a double-edged sword for defense and offense

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2013.06.013

Expression of toll-like receptors on breast tumors: taking a toll on tumor microenvironment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2013.06.013

Single circulating tumor cell detection and overall survival in nonmetastatic breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2013.06.013

Circulating tumor cells, disease progression, and survival in metastatic breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2013.06.013

The interplay between innate and adaptive immunity regulates cancer development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2013.06.013

Immune cells as mediators of solid tumor metastasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2013.06.013

The immunobiology of cancer immunosurveillance and immunoediting

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2013.06.013

Toll-like receptor-4 (TLR4) signaling augments chemokine-induced neutrophil migration by modulating cell surface expression of chemokine receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2013.06.013

Determination of HER2 status using both serum HER2 levels and circulating tumor cells in patients with recurrent breast cancer whose primary tumor was HER2 negative or of unknown HER2 status

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2013.06.013

Circulating tumor-specific DNA: a marker for monitoring efficacy of adjuvant therapy in cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2013.06.013

Increased NOS2 predicts poor survival in estrogen receptor-negative breast cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2013.06.013

Overexpression of matrix metalloproteinases and their inhibitors in mononuclear inflammatory cells in breast cancer correlates with metastasis-relapse

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2013.06.013

Study of TLR3, TLR4 and TLR9 in breast carcinomas and their association with metastasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2013.06.013

7 January 2021

The Hallmarks of Cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2013.06.013

Lipopolysaccharide-induced metastatic growth is associated with increased angiogenesis, vascular permeability and tumor cell invasion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2013.06.013

TLR signaling by tumor and immune cells: a double-edged sword

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2013.06.013

HER2-positive circulating tumor cells in breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2013.06.013

Innate immunity gone awry: linking microbial infections to chronic inflammation and cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2013.06.013

TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2013.06.013

Toll-like receptors, wound healing, and carcinogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2013.06.013

Toll-like receptor signaling in cell proliferation and survival

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2013.06.013

Circulating tumor cells in breast cancer: detection systems, molecular characterization, and future challenges

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2013.06.013

Triggering of Toll-like receptor 4 on metastatic breast cancer cells promotes αvβ3-mediated adhesion and invasive migration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2013.06.013

Biomarkers characterization of circulating tumour cells in breast cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2013.06.013

Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2013.06.013

Molecular pathways: toll-like receptors in the tumor microenvironment--poor prognosis or new therapeutic opportunity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2013.06.013

The application of Toll like receptors for cancer therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2013.06.013

Circulating tumor cells in breast cancer: a tool whose time has come of age

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2013.06.013

Toll-like receptors gene polymorphisms may confer increased susceptibility to breast cancer development.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2013.06.013

Statistical considerations for enumeration of circulating tumor cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2013.06.013

Reduced expression of Toll-like receptor 4 inhibits human breast cancer cells proliferation and inflammatory cytokines secretion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2013.06.013

Meta-analysis of the prognostic value of circulating tumor cells in breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2013.06.013

Immunological aspects of cancer chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2013.06.013

10.1016/J.YEXMP.2013.06.013

7 January 2021

Identifiers

DOI

1 reference

14 March 2018

PubMed ID

23831428

1 reference

14 March 2018